HK Stock Market Move | MEDBOT-B(02252) rises by more than 3% Overseas market new order growth accelerates The company deeply cultivates the core high-end medical region in Europe.

MEDBOT-B (02252) rose more than 3%, as of the time of writing, rose by 2.7%, trading at 35.04 Hong Kong dollars, with a transaction amount of 1.48 billion Hong Kong dollars. On the news front, recently, at the 93rd China International Medical Equipment Fair (CMEF), Han Xiaolu, the overseas sales director of Micro-invasive Siasun Robot & Automation, revealed in an interview that the speed of new orders in the overseas market is very fast, with overseas market new orders and sales revenue in 2026 increasing by over 400% compared to the same period last year. In addition, according to Han Xiaolu, in the core markets of Europe, Micro-invasive Siasun Robot & Automation is one of the few domestic brands that have truly achieved commercial installation, successfully entering high-end medical hubs such as Belgium, the UK, France, and Spain. As of early April 2026, Micro-invasive Siasun Robot & Automation has installed 23 of their Talimai endoscopic surgery machines, with 86 orders in hand; the management has guided that about 103-113 machines will be installed in the first half of 2026, with at least 200 machines annually, indicating that delivery bottlenecks have been resolved. The overseas market remains a core growth engine, covering regions such as South America, Asia, and Europe.